ANI Pharmaceuticals (ANIP) AI Analysis
Score
ANI Pharmaceuticals mixes growth with a still-reasonable multiple — Growth 76/100 with P/E 13.0, about 78% below its own multi-year median. Under the hood: P/E 13.0, about 78% below its own multi-year median, plus revenue compounding ~41% annually over recent years. Street targets still imply ~39% upside.